In pancreatic cancer studies, it shows unique value: it can identify transcript–protein mismatch phenomena, such as the 67% concordance rate of PD-1 mRNA and protein expression in CD8+ T cells; in addition, customized antibody panels can specifically detect exhausted T cell subsets, with a hazard ratio (HR) of 2.8 and p < 0.001, indicating a significant correlation with patient prognosis. The gene discussed is CD8A; the disease is pancreatic neoplasm.